| Name | Title | Contact Details |
|---|
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. The companys revolutionary ID/AST platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. In addition to the Accelerate ID/AST System development pipeline, the company also owns and licenses its proprietary OptiChem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Pelton Shepherd Industries is a Stockton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gnathos Dental Products is a Union, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For 25 years, we have set the standard for medical grade private label skincare. We have perfected the effectiveness of skincare products and have created an ideal private label experience. Designed for simplicity and efficiency, our branding process is one of the most streamlined and rewarding in the industry. We believe building loyalty to your own brand of quality skincare products is the key to taking your business to the next level and we are here to help you every step of the way.
CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.